RBC Capital sets a price target of $90 for NYSE:INSP, indicating a potential upside of approximately 10.66%.Baillie Gifford & Co. reduces its stake in INSP by 2.7%, selling 29,538 shares, while Texas Permanent School Fund Corp increases its holdings by 42.2%.INSP's stock price stands at $81.33, with a year's volatility ranging from $70.77 to $203.12 and a market capitalization of approximately $2.41 billion.Inspire Medical Systems, Inc. (NYSE:INSP) is a company that specializes in innovative medical solutio ...

Company Overview - ResMed is a medical equipment company based in San Diego, California, originally founded in Australia, specializing in cloud-connectable CPAP machines for obstructive sleep apnea treatment [2] - The company operates globally with over 10,000 employees and a presence in more than 140 countries, divided into two main business units: Sleep and Respiratory Care, and Software as a Service (SaaS) [3] - ResMed's products include industry-leading CPAP machines and software for durable medical equipment, focusing on out-of-hospital care [3][4] Market Performance - The ASX:RMD share price has decreased by 2.0% since the start of 2025 [1] - The S&P/ASX200 Healthcare Index has returned -4.53% per year over the last 5 years, contrasting with a 5.51% annual return from the broader ASX 200 [5] Revenue Stability - Healthcare spending is considered essential, leading to stable and consistent revenue streams, often referred to as 'sticky' revenue, which remains resilient during economic downturns [6] - Historical performance indicates that healthcare was the best-performing sector during the Global Financial Crisis (GFC) [6] Growth Potential - Global healthcare spending, particularly in the US, is projected to grow significantly, with estimates of 7% annual growth from 2022 to 2027, reaching US$819 billion [7] - Sub-sectors such as healthcare IT and SaaS are expected to see revenue growth exceeding 15% per year from 2024 to 2030, attracting investor interest [8] Ethical Investment Trends - A Morgan Stanley survey indicates that over half of investors plan to increase their allocation to sustainable investments in 2024, positioning healthcare sectors favorably for attracting new capital [9] Valuation Insights - ResMed shares currently have a price-to-sales ratio of 5.08x, below the 5-year average of 8.70x, suggesting that shares may be undervalued or that sales have increased [11]

Core Insights - David Gardner emphasizes a shift in investment strategy from the traditional "buy low, sell high" to "buy high and try not to sell," advocating for long-term holding of quality stocks [3][4] - Successful companies often emerge as leaders in new industries, with examples like Amazon and Netflix demonstrating the importance of being a first-mover [5][7] - Gardner argues that financial metrics alone do not capture the full value of a company, highlighting the significance of management quality, brand strength, and innovation [10][11][12] Investment Strategy - The traditional advice of "buy low, sell high" is criticized for potentially causing investors to miss out on growth opportunities [3] - Gardner's alternative strategy encourages buying high-quality stocks even at premium prices, with the expectation of holding them long-term [4] - The focus should be on the company's potential and leadership in emerging markets rather than solely on price fluctuations [5][7] Characteristics of Winning Stocks - Great stocks typically dominate their respective markets and are often first-movers in emerging industries [5][6] - Companies like Nvidia exemplify how late investments can still yield significant returns, as evidenced by a 48% increase in stock price over the past year [7] - Innovative companies can be identified even after they have established themselves, allowing for profitable investments [9] Valuation Perspective - Gardner suggests that being labeled as "overvalued" can indicate a stock's potential as a Rule Breaker investment [10] - Important attributes such as management quality and brand value are not reflected in traditional financial metrics, making them crucial for investment decisions [11][12] - Investors should not dismiss high-valuation stocks if other indicators suggest they are strong buys [12]

Group 1: Company Overview - Mineral Resources Limited (MIN) is a diversified Australian mining company focused on lithium and iron ore extraction in Western Australia [1][2] - ResMed (RMD) specializes in medical equipment, particularly cloud-connectable CPAP machines for treating obstructive sleep apnea, and is headquartered in San Diego, California [3][4] Group 2: Business Operations - MIN provides mining and engineering services through its subsidiary, CSI Mining Services, which operates across Western Australia, Queensland, and the Northern Territory [2] - ResMed operates two main business units: Sleep and Respiratory Care, and Software as a Service (SaaS), offering both medical equipment and software solutions for out-of-hospital care [4][5] Group 3: Financial Performance - MIN has experienced a revenue growth rate of 12.2% per year since 2021, reaching $5,278 million in FY24, but net profit has decreased from $1,270 million to $125 million, with a reported ROE of 3.2% [6][7] - RMD has seen a revenue growth rate of 13.6% per year since 2021, achieving $4,685 million in FY24, with net profit increasing from $475 million to $1,021 million, and a reported ROE of 22.7% [7]

Company Overview - ResMed is a medical equipment company based in San Diego, California, originally founded in Australia, specializing in cloud-connectable CPAP machines for obstructive sleep apnea treatment [2] - The company operates globally with over 10,000 employees and a presence in more than 140 countries, divided into two primary business units: Sleep and Respiratory Care, and Software as a Service (SaaS) [3] - Netwealth is a wealth management software business that provides a platform for financial planners, with over 140,000 account holders and $88 billion in funds under administration as of 2024 [5] Business Model and Services - ResMed's Sleep and Respiratory Care unit offers industry-leading CPAP machines, catering to a wide range of patients from those needing nightly therapy to those requiring life-support ventilation [3] - The SaaS unit provides software for durable or home medical equipment, enhancing out-of-hospital care [3][4] - Netwealth's platform allows users to manage investments, track performance, and access financial reports through a user-friendly interface [6] Financial Performance and Valuation - ResMed shares have a current price-sales ratio of 5.63x, significantly lower than its 5-year average of 8.70x, indicating potential undervaluation or increased sales [8] - In contrast, Netwealth shares trade at a price-sales ratio of 30.23x, above its 5-year average of 23.72x, suggesting a higher valuation relative to historical performance [9]